Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes –
– Humacyte's stem cell-derived islets observed to restore normal blood glucose in diabetic mice –
– Non-human primate models of BVP implantation showed islet survival and continued insulin production –
DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the presentation of positive preclinical progress of its development of a potential treatment for type 1 diabetes at two scientific meetings. Humacyte's BioVascular Pancreas (BVP) product candidate, currently in preclinical testing, incorporates stem cell-derived islets that are delivered using Humacyte's acellular tissue engineered vessel (ATEV) technology.
Posted In: HUMA